Conference Proceedings
A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome
Amer M Zeidan, Daniel A Pollyea, Jacqueline S Garcia, Andrew Brunner, Fernando Roncolato, Uma Borate, Olatoyosi Odenike, Ashish R Bajel, Anne Marie Watson, Katharina Gotze, Florian Nolte, Peter T Tan, Wan-Jen Hong, Martin Dunbar, Ying Zhou, Lori Gressick, William Ainsworth, Jason Harb, Ahmed Hamed Salem, John Hayslip Show all
BLOOD | AMER SOC HEMATOLOGY | Published : 2019
Abstract
Introduction Over-expression of the anti-apoptotic protein BCL-2 in MDS has been implicated in progression and drug resistance in MDS. Venetoclax (Ven), a selective, potent, orally bioavailable BCL-2 inhibitor, was recently approved in combination with HMAs or low dose cytarabine for the frontline management of older unfit pts with AML. In this study, we sought to evaluate the safety and efficacy of Ven in pts with R/R MDS. Methods This is an ongoing phase 1b, open-label, multicenter study in R/R MDS (NCT02966782). Key eligibility criteria include age ≥18 years, failure of HMA after receiving at least 4 cycles of Aza or 4 cycles of decitabine with..
View full abstract